# R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

> **NCT03018626** · PHASE3 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 402 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Etoposide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** Prednisone
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Vindesine
- **DRUG:** Bleomycin

## Key facts

- **NCT ID:** NCT03018626
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-27
- **Primary completion:** 2020-01
- **Final completion:** 2021-01
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03018626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03018626, "R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03018626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*